BioCentury | Jan 20, 2021
Emerging Company Profile

Aulos: Tackling the IL-2 space with computational biology

...Sanofi (Euronext:SAN; NASDAQ:SNY) through its acquisition of Synthorx Inc....
BioCentury | Dec 5, 2020
Finance

Seer posts triple-digit gain as trio of new listings adds to 2020’s record NASDAQ haul

...HER2-expressing solid tumors. CEO Laura Shawver joined the biotech this year, a few months after leading Synthorx Inc....
BioCentury | Sep 18, 2020
Emerging Company Profile

Synthekine launches with $82M to create new cytokine signals

...“superkines,” and helped lay the groundwork for variations on the approach from  Nektar Therapeutics (NASDAQ:NKTR), Synthorx Inc....
BioCentury | Aug 29, 2020
Product Development

Next-wave Th1 cytokine cancer therapies aim for more precise targeting

...groups, through the pharma’s $2.5 billion acquisition of Synthorx...
BioCentury | Aug 17, 2020
Deals

Via $3.4B Principia takeout, Sanofi can explore potential of Btk inhibitor beyond MS

...acquisition since it bought Ablynx N.V. for €3.9 billion in 2018. It paid $2.5 billion for Synthorx Inc....
BioCentury | Aug 5, 2020
Management Tracks

CureVac makes Haas’ CEO job permanent; plus Zhang now CEO of Legend and updates from Royalty, NBE, Black Diamond, VelosBio and more

...Inc. hired Enoch Kariuki as CFO, a new position. He was SVP, corporate development at Synthorx Inc....
BioCentury | Jul 29, 2020
Emerging Company Profile

Bright Peak synthesizing proteins like they’re small molecules with $35M from Versant

...anti-PD-1 mAb Opdivo nivolumab from Bristol Myers Squibb Co. (NYSE:BMY) (see “Clever PEGylation Payoff” ). Synthorx Inc....
BioCentury | Jul 17, 2020
Finance

Data Bytes: preclinical IPO performance trending up

...their list price, and six of that group gained at least 300%: synthetic biology company Synthorx Inc....
...last December: Audentes, which was acquired by Astellas Pharma Inc. (Tokyo:4503) for $3 billion; and Synthorx...
BioCentury | May 27, 2020
Deals

Sanofi's sale of Regeneron stake for $11B could set stage for both companies' growth through M&A

...seek takeouts that bolster its innovative cancer pipeline. In January, Sanofi closed it acquisition of Synthorx Inc....
BioCentury | May 20, 2020
Management Tracks

Former Allergan execs join Merck spinout; plus Ping An ousts Tao, and updates from Mirati, Evox, Ardelyx, Akcea, Horama and more

...succeeded by Joseph Leveque, who was hired as CMO; Leveque held the same role at Synthorx Inc....
Items per page:
1 - 10 of 39
BioCentury | Jan 20, 2021
Emerging Company Profile

Aulos: Tackling the IL-2 space with computational biology

...Sanofi (Euronext:SAN; NASDAQ:SNY) through its acquisition of Synthorx Inc....
BioCentury | Dec 5, 2020
Finance

Seer posts triple-digit gain as trio of new listings adds to 2020’s record NASDAQ haul

...HER2-expressing solid tumors. CEO Laura Shawver joined the biotech this year, a few months after leading Synthorx Inc....
BioCentury | Sep 18, 2020
Emerging Company Profile

Synthekine launches with $82M to create new cytokine signals

...“superkines,” and helped lay the groundwork for variations on the approach from  Nektar Therapeutics (NASDAQ:NKTR), Synthorx Inc....
BioCentury | Aug 29, 2020
Product Development

Next-wave Th1 cytokine cancer therapies aim for more precise targeting

...groups, through the pharma’s $2.5 billion acquisition of Synthorx...
BioCentury | Aug 17, 2020
Deals

Via $3.4B Principia takeout, Sanofi can explore potential of Btk inhibitor beyond MS

...acquisition since it bought Ablynx N.V. for €3.9 billion in 2018. It paid $2.5 billion for Synthorx Inc....
BioCentury | Aug 5, 2020
Management Tracks

CureVac makes Haas’ CEO job permanent; plus Zhang now CEO of Legend and updates from Royalty, NBE, Black Diamond, VelosBio and more

...Inc. hired Enoch Kariuki as CFO, a new position. He was SVP, corporate development at Synthorx Inc....
BioCentury | Jul 29, 2020
Emerging Company Profile

Bright Peak synthesizing proteins like they’re small molecules with $35M from Versant

...anti-PD-1 mAb Opdivo nivolumab from Bristol Myers Squibb Co. (NYSE:BMY) (see “Clever PEGylation Payoff” ). Synthorx Inc....
BioCentury | Jul 17, 2020
Finance

Data Bytes: preclinical IPO performance trending up

...their list price, and six of that group gained at least 300%: synthetic biology company Synthorx Inc....
...last December: Audentes, which was acquired by Astellas Pharma Inc. (Tokyo:4503) for $3 billion; and Synthorx...
BioCentury | May 27, 2020
Deals

Sanofi's sale of Regeneron stake for $11B could set stage for both companies' growth through M&A

...seek takeouts that bolster its innovative cancer pipeline. In January, Sanofi closed it acquisition of Synthorx Inc....
BioCentury | May 20, 2020
Management Tracks

Former Allergan execs join Merck spinout; plus Ping An ousts Tao, and updates from Mirati, Evox, Ardelyx, Akcea, Horama and more

...succeeded by Joseph Leveque, who was hired as CMO; Leveque held the same role at Synthorx Inc....
Items per page:
1 - 10 of 39